Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021 : results from the European registry on H. pylori management (Hp-EuReg)

Hp-EuReg investigators

Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021 : results from the European registry on H. pylori management (Hp-EuReg)

background Bismuth quadruple therapies (BQTs) including bismuth, a proton pump inhibitor (PPI) and two antibiotics have been shown to be highly effective for treating Helicobacter pylori infection even in areas of high bacterial antibiotic resistance. Objective To describe the time trends of use, ef...

Descripción completa

Detalles Bibliográficos
Autor:	Hp-EuReg investigators
Tipo de recurso:	artículo
Fecha de publicación:	2025
País:	España
Institución:	Universidad de Málaga
Repositorio:	DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria
Idioma:	inglés
OAI Identifier:	oai:ddfv.ufv.es:10641/6937
Acceso en línea:	https://hdl.handle.net/10641/6937
Access Level:	acceso abierto
Palabra clave:	Antibiotic therapy Helicobacter pylori - treatment Helicobacter therapy Gastroenterology Yes yes

id	ES_43f170eafbf997ae58c8adff4f0fcf1c
oai_identifier_str	oai:ddfv.ufv.es:10641/6937
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021 : results from the European registry on H. pylori management (Hp-EuReg)Hp-EuReg investigatorsAntibiotic therapyHelicobacter pylori - treatmentHelicobacter therapyGastroenterologyYesyesbackground Bismuth quadruple therapies (BQTs) including bismuth, a proton pump inhibitor (PPI) and two antibiotics have been shown to be highly effective for treating Helicobacter pylori infection even in areas of high bacterial antibiotic resistance. Objective To describe the time trends of use, effectiveness and safety of BQT in Europe using the European Registry on Helicobacter pylori Management (Hp-EuReg). Design Patients registered in the Hp-EuReg from 2013 to 2021 who had received BQT were included. The regimens prescribed, the number of eradication attempts, effectiveness, adherence and safety were analysed. The effectiveness was assessed by modified intention to treat (mITT). Time-trend and multivariate analyses were performed to determine variables that predicted treatment success. results Of the 49 690 patients included in the Hp-EuReg, 15 582 (31%) had received BQT. BQT use increased from 8.6% of all treatments in 2013 to 39% in 2021. Single-capsule BQT—containing bismuth, metronidazole and tetracycline—plus a PPI (single-capsule BQT, ScBQT) was the most frequent treatment mode (43%). Schemes that obtained an effectiveness above 90% were the 10-day ScBQT and 14-day BQT using tetracycline plus metronidazole, or amoxicillin plus either clarithromycin or metronidazole. Only ScBQT achieved above 90% cure rates in all the geographical areas studied. Using the ScBQT scheme, adherence, the use of standard or high-dose PPIs, 14-day prescriptions and the use of BQT as first-line treatment were significantly associated with higher mITT effectiveness. Conclusion The use of BQT increased notably in Europe over the study period. A 10-day ScBQT was the scheme that most consistently achieved optimal effectiveness.Facultad de Medicina20252025-01-0120252025-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10641/6937reponame:DDFV. Repositorio Institucional de la Universidad Francisco de Vitoriainstname:Universidad de MálagaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:ddfv.ufv.es:10641/69372026-06-11T12:44:57Z
dc.title.none.fl_str_mv	Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021 : results from the European registry on H. pylori management (Hp-EuReg)
title	Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021 : results from the European registry on H. pylori management (Hp-EuReg)
spellingShingle	Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021 : results from the European registry on H. pylori management (Hp-EuReg) Hp-EuReg investigators Antibiotic therapy Helicobacter pylori - treatment Helicobacter therapy Gastroenterology Yes yes
title_short	Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021 : results from the European registry on H. pylori management (Hp-EuReg)
title_full	Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021 : results from the European registry on H. pylori management (Hp-EuReg)
title_fullStr	Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021 : results from the European registry on H. pylori management (Hp-EuReg)
title_full_unstemmed	Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021 : results from the European registry on H. pylori management (Hp-EuReg)
title_sort	Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021 : results from the European registry on H. pylori management (Hp-EuReg)
dc.creator.none.fl_str_mv	Hp-EuReg investigators
author	Hp-EuReg investigators
author_facet	Hp-EuReg investigators
author_role	author
dc.contributor.none.fl_str_mv	Facultad de Medicina
dc.subject.none.fl_str_mv	Antibiotic therapy Helicobacter pylori - treatment Helicobacter therapy Gastroenterology Yes yes
topic	Antibiotic therapy Helicobacter pylori - treatment Helicobacter therapy Gastroenterology Yes yes
description	background Bismuth quadruple therapies (BQTs) including bismuth, a proton pump inhibitor (PPI) and two antibiotics have been shown to be highly effective for treating Helicobacter pylori infection even in areas of high bacterial antibiotic resistance. Objective To describe the time trends of use, effectiveness and safety of BQT in Europe using the European Registry on Helicobacter pylori Management (Hp-EuReg). Design Patients registered in the Hp-EuReg from 2013 to 2021 who had received BQT were included. The regimens prescribed, the number of eradication attempts, effectiveness, adherence and safety were analysed. The effectiveness was assessed by modified intention to treat (mITT). Time-trend and multivariate analyses were performed to determine variables that predicted treatment success. results Of the 49 690 patients included in the Hp-EuReg, 15 582 (31%) had received BQT. BQT use increased from 8.6% of all treatments in 2013 to 39% in 2021. Single-capsule BQT—containing bismuth, metronidazole and tetracycline—plus a PPI (single-capsule BQT, ScBQT) was the most frequent treatment mode (43%). Schemes that obtained an effectiveness above 90% were the 10-day ScBQT and 14-day BQT using tetracycline plus metronidazole, or amoxicillin plus either clarithromycin or metronidazole. Only ScBQT achieved above 90% cure rates in all the geographical areas studied. Using the ScBQT scheme, adherence, the use of standard or high-dose PPIs, 14-day prescriptions and the use of BQT as first-line treatment were significantly associated with higher mITT effectiveness. Conclusion The use of BQT increased notably in Europe over the study period. A 10-day ScBQT was the scheme that most consistently achieved optimal effectiveness.
publishDate	2025
dc.date.none.fl_str_mv	2025 2025-01-01 2025 2025-01-01
dc.type.none.fl_str_mv	journal article http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://hdl.handle.net/10641/6937
url	https://hdl.handle.net/10641/6937
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2 http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2 http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.source.none.fl_str_mv	reponame:DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria instname:Universidad de Málaga
instname_str	Universidad de Málaga
reponame_str	DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria
collection	DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869407059032670208
score	15,81155

Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021 : results from the European registry on H. pylori management (Hp-EuReg)

Similares en LA Referencia